Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
1.020
+0.210 (25.91%)
At close: Jun 6, 2025, 4:00 PM
1.070
+0.050 (4.90%)
After-hours: Jun 6, 2025, 6:08 PM EDT
Neumora Therapeutics Employees
Neumora Therapeutics had 110 employees as of December 31, 2024. The number of employees decreased by 14 or -11.29% compared to the previous year.
Employees
110
Change (1Y)
-14
Growth (1Y)
-11.29%
Revenue / Employee
n/a
Profits / Employee
-$2,345,982
Market Cap
164.98M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 110 | -14 | -11.29% |
Dec 31, 2023 | 124 | 30 | 31.91% |
Dec 31, 2022 | 94 | 6 | 6.82% |
Dec 31, 2021 | 88 | 35 | 66.04% |
Dec 31, 2020 | 53 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
NMRA News
- 24 days ago - Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 25 days ago - Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - GlobeNewsWire
- 2 months ago - NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - PRNewsWire
- 2 months ago - NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - PRNewsWire
- 2 months ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 7, 2025 in Neumora Therapeutics, Inc. Lawsuit - NMRA - PRNewsWire
- 2 months ago - NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm - PRNewsWire
- 2 months ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Neumora Therapeutics - GlobeNewsWire